Results 161 to 170 of about 1,202,565 (290)

Bayesian Model Averaging of Parametric Coalescent Models for Phylodynamic Inference. [PDF]

Mol Biol Evol
Xu Y, Chen K, Xie D, Drummond AJ.
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Robust Bayesian Model Averaging Meta-Analysis of Menstrual Disorders in COVID-19 Survivors: A Methodological Meta-Analysis Study. [PDF]

Health Sci Rep
Falahati G, Biglarian A, Behboudi-Gandevani S, Bidhendi-Yarandi R.   +3 more
europepmc   +1 more source

Estimation for volunteer web survey samples using a model-averaging approach. [PDF]

J Appl Stat, 2023
Liu Z, Zheng J, Tu C, Pan Y.
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

The simple multivariable model for predicting liver fibrosis in Vietnamese male adults: a combination of Bayesian model averaging and stepwise method. [PDF]

PeerJ
Nguyen NN, Nguyen BT, Le HTN, Dang HN, Pham HM, Ngo DD, Nguyen DKT, Tran TTT, Kim HT, Mai TNH.   +9 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Bayesian model averaging based deep learning forecasts of inpatient bed occupancy in mental health facilities. [PDF]

Sci Rep
Avinash G, Mishra S.
europepmc   +1 more source

Improved runoff forecasting based on time-varying model averaging method and deep learning. [PDF]

PLoS One, 2022
Ran J, Cui Y, Xiang K, Song Y.
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source